| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| - | - | 4,700 | ₹4.05 -3.57% | 1,000166.66% |
| - | - | 4,800 | ₹3.4 13.33% | 1,875-53.12% |
| 2500% | ₹695.4 0% | 4,900 | ₹5.75 -8.73% | 4,8752.63% |
| 5000% | ₹521.2 0% | 4,950 | ₹18.95 0% | 6250% |
| - | - | 5,000 | ₹7.5 -22.27% | 5,125-4.65% |
| - | - | 5,050 | ₹71.75 0% | 5000% |
| 1250% | ₹395.9 0% | 5,100 | ₹10.25 -21.15% | 7,00033.33% |
| 1,6250% | ₹424.35 0% | 5,150 | ₹52.65 0% | 1,0000% |
| 2500% | ₹427.5 0% | 5,200 | ₹15.45 -25% | 11,1254.70% |
| 8750% | ₹280.45 0.28% | 5,250 | ₹38.85 0% | 1,3750% |
| 625150% | ₹361.1 49.15% | 5,300 | ₹26.5 -22.05% | 9,50018.75% |
| - | - | 5,350 | ₹33.6 -37.43% | 1,875-6.25% |
| 2,875-11.53% | ₹247.65 -4.75% | 5,400 | ₹44.2 -20% | 14,750-14.49% |
| 2,375-9.52% | ₹241.35 9.72% | 5,450 | ₹56.5 -19.34% | 9,125-9.87% |
| 30,375-0.40% | ₹206.55 11.01% | 5,500 | ₹71.5 -17.43% | 24,3752.09% |
| 11,3758.33% | ₹174.85 9% | 5,550 | ₹89 -18.31% | 10,6256.25% |
| 38,500-11.74% | ₹144.65 9.74% | 5,600 | ₹110 -15.99% | 16,00011.30% |
| 14,6250.86% | ₹118.15 7.85% | 5,650 | ₹170 0% | 8750% |
| 19,2508.45% | ₹98 7.51% | 5,700 | ₹175.5 -5.18% | 3,000-11.11% |
| 2,625-8.69% | ₹81.7 18.66% | 5,750 | ₹349.05 0% | 2500% |
| 17,625-14.02% | ₹64 8.47% | 5,800 | ₹250 -4.45% | 2,375-5% |
| 3,250-21.21% | ₹51.15 6.56% | 5,850 | - | - |
| 7,3757.27% | ₹39 40.03% | 5,900 | - | - |
| 3750% | ₹21.25 -0.23% | 5,950 | - | - |
| 42,0000% | ₹25 9.89% | 6,000 | - | - |
| 1,0000% | ₹34.05 0% | 6,050 | ₹676.2 0% | 1250% |
| 7,000-15.15% | ₹15.55 16.91% | 6,100 | ₹839.7 0% | 6250% |
| 1250% | ₹23.4 0% | 6,150 | ₹710 0% | 2500% |
| 12,62574.13% | ₹9.65 8.42% | 6,200 | ₹636.2 3.2% | 500-55.55% |
| 6250% | ₹14.4 0% | 6,300 | ₹853.2 0% | 1250% |
| 14,750-0.84% | ₹5.9 19.19% | 6,350 | - | - |
| 1,5000% | ₹3.9 -2.5% | 6,400 | ₹995 0% | 1250% |
| 4,1250% | ₹11.45 0% | 6,450 | - | - |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
